KRYS - Goldman starts Krystal Biotech at buy cites Vyjuvek launch
2023-11-20 15:03:53 ET
More on Krystal Biotech
- Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Call Transcript
- Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement
- Krystal Biotech Q3 2023 Earnings Preview
- Cantor starts Krystal Biotech at overweight, cites Vyjuvek launch
- Seeking Alpha’s Quant Rating on Krystal Biotech
For further details see:
Goldman starts Krystal Biotech at buy, cites Vyjuvek launch